Achieve Life Sciences

Intangible assets: moderate. The brand is not yet built, but the clinical dossier is strong and the asset should qualify for up to 7.5 years of U.S. regulatory data exclusivity if approved.

Composition‑of‑matter patents are not available for this natural product; the company relies on regulatory exclusivity, formulations/dosing IP, and exclusive supply with Sopharma, which weakens long‑term defensibility. Switching costs: low; prescribers can rotate among generics (varenicline, bupropion) and OTC NRT. Network effects: none.

Cost advantage: potential manufacturing simplicity and low side‑effect profile may support adherence but do not constitute structural cost leadership. Efficient scale: limited; smoking‑cessation is a large, competitive category. Weighted view yields a modest moat given exclusivity plus a potentially differentiated tolerability profile.